The International thoracic organ transplant registry of the international society for heart and lung transplantation: Thirty-ninth adult heart transplantation report—2022; focus on transplant for restrictive heart disease

This 39th annual international adult heart transplant report focuses on transplantation for heart disease with restrictive physiology, that is, restrictive cardiomyopathies and hypertrophic cardiomyopathy, based on data submitted to the International Society for Heart and Lung Transplantation (ISHLT) Thoracic Organ Transplant (TTX) Registry between January 1992 and June 2018. Restrictive cardiomyopathy (RCM) refers to a heterogeneous group of cardiomyopathies that includes amyloid, sarcoid, radiation and/or chemotherapy-induced cardiomyopathy, and other types of heart disease that all share restrictive physiology, and reduced or normal diastolic and systolic volumes in 1 or both ventricles. 1 Seferovic PM Polovina M Bauersachs J et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019; 21: 553-576 Crossref PubMed Scopus (132) Google Scholar Hypertrophic cardiomyopathy (HCM) is classified separately according to the World Heart Federation and MOGE(S) classification but will be included in this report because RCM and HCM share restrictive physiology, and may represent a different phenotypic expression of the same genotype (i.e., autosomal dominant inherited mutations in the desmin, alpha B crystalline, alpha-actinin 2, or beta-myosin heavy chain 7 genes). 2 Arbustini E Narula N Dec GW et al. The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. J Am Coll Cardiol. 2013; 62: 2046-2072 Crossref PubMed Scopus (147) Google Scholar